Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202522309

Vitamin B6 (Pyridoxine): Pharmacological Properties, Clinical Applications, and Nutritional Implications

Faris Hulayyil Mohammed Alotaibi [(1)] , Tariq Mohammed Hadi Marwani [(2)] , Abdullah Mohammed Hadi Marwani [(3)] , Khudhayr Abdulrhman Alanazi [(3)] , Atheer Yahya Alharthi [(4)] , Layla Yousef Ahmad Albatyan [(5)] , Khalil Naji Almutairi [(6)] , Abdulaziz Ibraheem Alrasheed [(7)] , Abdulaziz Mohammed Yahya Moafa [(8)] , Sultanah Mohammed Jaber Aljaber [(9)]

(1) Dawadmi General Hospital, Ministry of Health, Saudi Arabia,
(2) Ministry of Health Branch – Jeddah, Saudi Arabia,
(3) King Abdulaziz Hospital, Jeddah, Ministry of Health, Saudi Arabia,
(4) King Abdulaziz Hospital, Ministry of Health, Saudi Arabia,
(5) Al Salhiya Health Center, Al-Ahsa, Ministry of Health, Saudi Arabia,
(6) Medical Services – Ministry of Interior, Saudi Arabia,
(7) General Medical Authority, Riyadh, Ministry of Health, Saudi Arabia,
(8) Damad General Hospital, Ministry of Health, Saudi Arabia,
(9) Alharm Hospital – Madinah, Ministry of Health, Saudi Arabia

Abstract

Background: Vitamin B6 (pyridoxine) is a water-soluble vitamin essential for human physiology, primarily through its active coenzyme form, pyridoxal 5-phosphate (PLP). PLP is a crucial cofactor for over 100 enzymes involved in amino acid, carbohydrate, and lipid metabolism, neurotransmitter synthesis, and homocysteine regulation. Deficiency can arise from poor diet, malabsorption, chronic alcoholism, renal disease, and interactions with medications like isoniazid and certain antiepileptics.

Aim: This review aims to consolidate the pharmacological properties, clinical applications, and nutritional implications of vitamin B6, detailing its mechanisms, indications, administration, safety, and the importance of interprofessional management.

Methods: A comprehensive narrative review was conducted, synthesizing information on vitamin B6's biochemistry, pharmacokinetics, therapeutic uses, and toxicity from available literature.

Results: Vitamin B6 has well-defined roles in treating nutritional deficiencies and specific dependency syndromes (e.g., pyridoxine-dependent epilepsy), and as an antidote in isoniazid overdose. It is FDA-approved in a combination product for nausea in pregnancy. However, evidence for its efficacy in other conditions like premenstrual syndrome or carpal tunnel syndrome is inconsistent. While safe at recommended doses, chronic high-dose intake (>1g/day) can cause a dose-dependent, often reversible sensory neuropathy.

Conclusion: Vitamin B6 is fundamental to numerous metabolic processes. Its clinical use ranges from unequivocal indications for deficiency and specific genetic disorders to more empirical applications. Careful dose management and interprofessional collaboration are essential to maximize therapeutic benefits and minimize the risk of neurotoxicity from excessive intake.

Keywords: Vitamin B6, Pyridoxine, Pyridoxal 5-phosphate, Deficiency, Neuropathy, Isoniazid, Clinical Applications, Toxicity.

Introduction

Vitamin B6, commonly referred to as pyridoxine, is a water-soluble micronutrient that is indispensable for normal human physiology because of its conversion in vivo to a family of enzymatically active derivatives that participate in a wide spectrum of metabolic processes. Once absorbed, vitamin B6 is transformed into several interconvertible forms that collectively support the catalytic activity of more than one hundred distinct enzymes, underscoring its central role in intermediary metabolism and cellular homeostasis.[1][2] In nature, vitamin B6 exists predominantly as three closely related vitamers: pyridoxine (PN), pyridoxal (PL), and pyridoxamine (PM). Although structurally distinct, these compounds share the capacity to be phosphorylated and oxidized within human tissues to generate the bioactive coenzyme pyridoxal 5-phosphate (PLP, also referred to as P5P), which represents the principal functional form of vitamin B6 in the

*Corresponding author e-mail: faris91@gmail.com (Faris Hulayyil Mohammed Alotaibi).

Receive Date: 13 November 2025, Revise Date: 09 December 2025, Accept Date: 12 December 2025

body.[1][2] PLP serves as an essential cofactor for numerous enzymes involved in amino acid transamination, decarboxylation, and racemization, thereby integrating vitamin B6 into protein and amino acid metabolism at multiple regulatory points.[1] Beyond its crucial contribution to amino acid handling, PLP also supports key reactions in carbohydrate and lipid metabolism, participates in the synthesis of several neurotransmitters and neuromodulators, and influences pathways linked to one-carbon metabolism and homocysteine regulation. Through these mechanisms, vitamin B6 is further implicated in glycogen breakdown (glycogenolysis) and the generation of glucose from non-carbohydrate substrates (gluconeogenesis), linking its activity to energy balance and glucose homeostasis.[3][4]

Despite this extensive metabolic importance, only a limited number of medicinal products containing pyridoxine or its analogs have received formal regulatory approval. In the United States, there are currently two US Food and Drug Administration (FDA)–approved pharmaceutical preparations that incorporate pyridoxine or a related compound. The first is a parenteral multivitamin formulation that includes vitamin B6 among other water-soluble and fat-soluble vitamins, indicated for the prevention of vitamin deficiencies in pediatric and adult patients who require total or partial parenteral nutrition.[5] This preparation is intended to compensate for the absence of enteral intake and to maintain adequate vitamin status in patients wholly or partially dependent on intravenous nutrition. The second FDA-approved use is an oral fixed-dose combination of doxylamine succinate and pyridoxine hydrochloride, in tablet form, specifically indicated for the management of nausea and vomiting of pregnancy that has not responded adequately to conservative measures such as dietary modification and lifestyle interventions.[6] In this context, pyridoxine functions as a therapeutic adjunct with an established safety profile in pregnancy, contributing to symptom control in a condition that can significantly impair maternal well-being and nutritional status. The clearest and most direct indication for vitamin B6 supplementation is the correction of established deficiency states. True dietary insufficiency of vitamin B6 in isolation is relatively uncommon in otherwise healthy individuals consuming a varied diet, but deficiency can arise secondary to a range of clinical conditions and pharmacological exposures. Impaired renal function, including chronic kidney disease, can interfere with vitamin metabolism, increasing the risk of low circulating PLP levels.[7] Autoimmune disorders and systemic inflammatory states may also alter vitamin B6 status through changes in protein binding, increased utilization, or reduced intake. Furthermore, chronic high alcohol consumption is a well-recognized contributor to deficiency, as ethanol interferes with hepatic metabolism, intestinal absorption, and the phosphorylation of B6 vitamers, thereby lowering functional PLP levels.[8]



Fig. 1: Vitamin B6 Structure.

Numerous medications are associated with clinically significant depletion of vitamin B6, making supplementation important in specific therapeutic contexts. Among these, isoniazid and cycloserine, both used in the treatment of tuberculosis, form hydrazone complexes with pyridoxal phosphate and thereby inactivate PLP-dependent enzymes, increasing the risk of neurotoxicity unless prophylactic pyridoxine is co-administered.[9] Several antiepileptic drugs, including valproic acid, phenytoin, carbamazepine, and primidone, may interfere with vitamin B6 metabolism or utilization, predisposing patients to deficiency, especially with prolonged use.[10] Other medications such as hydralazine, theophylline, and certain additional agents have also been implicated in lowering vitamin B6 status, making supplementation a rational supportive measure in selected patients receiving long-term therapy.[11] Clinically, vitamin B6 deficiency manifests with a range of cutaneous, hematologic, neurologic, and psychiatric features, many of which reflect the nutrient's essential contributions to protein metabolism, neurotransmitter synthesis, and heme production. Typical dermatologic findings can include seborrheic dermatitis–like eruptions, particularly in facial and intertriginous areas, as well as cheilosis and glossitis, indicating impaired epithelial integrity.[12] On the hematologic level, microcytic anemia may develop due to impaired heme synthesis, as PLP serves as a cofactor for δ-aminolevulinic acid synthase, the rate-limiting enzyme in heme biosynthesis.[13] Neurologic manifestations may encompass peripheral neuropathy, epileptiform seizures or convulsions, and electroencephalographic abnormalities, reflecting disrupted neurotransmitter balance and altered excitatory–inhibitory signaling in the central nervous system.[12][13] Psychiatric symptoms such as depression, confusion, or irritability may also emerge, alongside evidence of reduced immune competence, as vitamin B6 is required for optimal lymphocyte proliferation and interleukin-2 production.[14] When these clinical features occur in the presence of known risk factors, vitamin B6 supplementation is clearly indicated as part of the therapeutic strategy.

Beyond acquired deficiency, there exists a group of rare hereditary disorders in which vitamin B6 plays a unique and life-preserving therapeutic role. These inborn errors of metabolism are often due to mutations affecting the binding sites or structural configuration of PLP-dependent enzymes, diminishing but not entirely abolishing their affinity for the coenzyme. In such conditions, providing very high pharmacologic doses of pyridoxine can increase intracellular PLP concentrations sufficiently to drive residual enzymatic activity and restore metabolic flux. These disorders are collectively referred to as vitamin B6 dependency syndromes.[15] Clinically, they encompass entities such as pyridoxine-dependent seizures in the newborn, in which intractable convulsions respond dramatically to high-dose vitamin B6; xanthurenic aciduria, cystathioninuria, and primary hyperoxaluria, each involving abnormalities in amino acid or organic acid metabolism; homocystinuria related to cystathionine β-synthase dysfunction; certain forms of sideroblastic anemia linked to impaired heme synthesis; and gyrate atrophy with ornithinuria, a retinal degenerative condition associated with disrupted ornithine metabolism.[15] In all of these disorders, vitamin B6 supplementation serves not as a simple nutritional replacement but as targeted pharmacologic therapy for a genetically determined enzymatic defect. Pyridoxine also has important roles in clinical toxicology. Because of its biochemical interactions with hydrazine derivatives and certain xenobiotics, vitamin B6 is employed as an antidotal or adjunctive agent in several poisoning scenarios. In cases of isoniazid overdose, massive doses of pyridoxine are administered to counteract seizure activity by replenishing PLP and restoring γ-aminobutyric acid (GABA) synthesis, which is otherwise suppressed by the drug.[16] Similar principles underlie its use in poisoning from false morel mushrooms (Gyromitra species), which contain gyromitrin and related hydrazine compounds, as well as in hydrazine exposure from industrial sources. Pyridoxine has also been utilized in the management of certain cases of ethylene glycol toxicity and crimidine poisoning, where disturbances in GABAergic neurotransmission and metabolic derangements may be mitigated by restoring PLP-dependent enzyme function.[16]

Additional indications for vitamin B6 have been explored in the realms of endocrinology, obstetrics, and gynecology. Limited evidence suggests that pyridoxine may have a suppressive effect on lactation, although this is not standard practice and is rarely recommended in current clinical guidelines.[17] Vitamin B6 has also been proposed as a supportive therapy for alleviating some adverse effects associated with combined oral contraceptives, such as mood changes, depression, and nausea, presumably via modulation of neurotransmitter synthesis.[17] However, the quality and consistency of evidence in these applications remain variable, and such uses are generally considered adjunctive or experimental. A range of other potential therapeutic roles for vitamin B6 has been studied, with often conflicting or inconclusive results. Investigations have evaluated pyridoxine supplementation in gestational diabetes, premenstrual syndrome, carpal tunnel syndrome, morning sickness beyond the approved doxylamine–pyridoxine combination, and essential hypertension, among other conditions.[17] While some individual studies report symptomatic benefit, meta-analyses and larger controlled trials have not consistently demonstrated robust or reproducible effects, and vitamin B6 is therefore not universally accepted as a primary treatment in these settings. Despite the limited high-quality evidence for many of these conditions, pyridoxine continues to be used empirically in a variety of clinical contexts, reflecting both its central metabolic role and its generally favorable safety profile at conventional doses. Reported off-label or investigational uses include atopic dermatitis, dental caries prevention, acute alcohol intoxication, autism spectrum disorder, various diabetic complications, Down syndrome, schizophrenia, Huntington chorea, and steroid-dependent asthma.[18][19] In most of these indications, data derive from small, heterogeneous studies or anecdotal clinical experience, and vitamin B6 should be viewed as an adjunct rather than a substitute for standard evidence-based therapy.

Emerging research has also explored potential associations between vitamin B6 status and oncologic outcomes. Epidemiologic studies in humans have suggested an inverse relationship between dietary or plasma B6 levels and the risk of colorectal cancer, with higher intake linked to a lower incidence of disease.[20] Although causality has not been definitively established, these findings raise the possibility that optimal PLP status may exert protective effects through modulation of one-carbon metabolism, DNA synthesis and repair, or inflammatory pathways. Experimental work in animal models further supports a possible antineoplastic effect, with high vitamin B6 levels shown to inhibit in-vitro hepatic tumor cell proliferation in rats.[21] These data, while preliminary, point to a potential role for vitamin B6 in cancer prevention or adjunctive therapy that warrants further mechanistic and clinical investigation. Taken together, the indications for vitamin B6 range from unequivocal, such as the treatment and prevention of deficiency and the management of specific dependency syndromes or toxin exposures, to exploratory or adjunctive roles in a broad array of clinical conditions. Its central biochemical position, relative safety, and wide physiologic impact continue to motivate research aimed at clarifying where pyridoxine can be most

effectively and appropriately integrated into modern therapeutic practice.[1][2][3][4][5].

Mechanism of Action

The biologic activity of vitamin B6 is mediated predominantly through its phosphorylated aldehyde derivative, pyridoxal 5-phosphate (PLP), which functions as a versatile coenzyme in numerous enzymatic reactions. PLP is uniquely suited to catalyze a broad repertoire of transformations involving amino acids, including transamination, decarboxylation, racemization, and various β- and γ-elimination and substitution reactions.[22] These reactions may occur with PLP bound within the active site of specific enzymes or, less commonly, in a transient free state. The key to PLP's catalytic power lies in its ability to form a Schiff base (aldimine) with the ε-amino group of an active-site lysine residue or with the α-amino group of the substrate amino acid. Once this internal or external aldimine is formed, PLP acts as an "electron sink," stabilizing carbanionic intermediates by delocalizing negative charge into its conjugated ring system.[22] The electron-withdrawing nature of the PLP pyridinium ring destabilizes the carbon–hydrogen bonds at the α-carbon of the amino acid substrate. This destabilization lowers the activation energy required for cleavage or rearrangement of specific bonds adjacent to the α-carbon, thereby greatly accelerating otherwise slow non-enzymatic reactions.[22] Through this mechanism, PLP facilitates the reversible transfer of amino groups in transamination reactions, the removal of carboxyl groups in decarboxylation pathways critical for neurotransmitter synthesis, the interconversion of D- and L-amino acids via racemization, and the cleavage or substitution of side-chain groups in elimination reactions. Collectively, these activities place PLP at the center of amino acid catabolism, neurotransmitter production, and numerous biosynthetic routes, illustrating the crucial mechanistic role of vitamin B6 in maintaining metabolic flexibility and cellular signaling.



Fig. 2: Vitamin B6 nutrition and metabolism.

The metabolic handling of vitamin B6 begins at the level of intestinal absorption. The three principal vitamers—pyridoxine (PN), pyridoxamine (PM), and pyridoxal (PL)—are absorbed rapidly from food and oral pharmaceutical preparations by the mucosal cells of the small intestine.[23] In contrast, phosphorylated derivatives of these vitamers, which may be present in certain dietary sources, are not absorbed intact and must first undergo dephosphorylation by intestinal phosphatases at the brush border prior to uptake.[23] Once dephosphorylated, the non-phosphorylated forms can be transported across the enterocyte membrane. Absorption of vitamin B6 analogs in the intestine occurs largely via passive diffusion, a process that is not saturable within the range of normal dietary intake.[24][25] This mode of transport means that a relatively large fraction of ingested pyridoxine, pyridoxamine, and pyridoxal can be efficiently absorbed without the constraints of carrier-mediated systems, contributing to the generally high oral bioavailability of the vitamin.[24][25] After entry into the enterocyte, these vitamers are released into the portal circulation and transported to the liver for further metabolic conversion. Within hepatocytes, pyridoxine and pyridoxamine (PN and PM) undergo phosphorylation by the enzyme pyridoxal kinase, forming pyridoxine 5-phosphate (PNP) and pyridoxamine 5-phosphate (PMP), respectively.[24] Pyridoxal (PL) is similarly phosphorylated to PLP when required. PNP and PMP are then oxidized by pyridoxine (pyridoxamine) phosphate oxidase (PNP oxidase) to generate PLP, the principal coenzyme form.[24] Crucially, this oxidative step is largely confined to the liver and, to a lesser extent, the mucosal cells of the small intestine, because PNP oxidase activity is limited or absent in most other tissues. As a result, the liver serves as the central processing hub for converting absorbed vitamin B6 vitamers into their active coenzyme form.

Once formed in the liver, PLP faces the challenge of cellular transport, as cell membranes are relatively impermeable to phosphorylated compounds. To facilitate systemic distribution, PLP is first dephosphorylated by phosphohydrolase enzymes to regenerate PL, which can then diffuse or be transported across cell membranes into the circulation.[24][26] Within the bloodstream, PL can be rephosphorylated to PLP inside target tissues. Alternatively, in the liver, PLP may be directly bound to plasma proteins, particularly albumin, and released into the circulation as a PLP–albumin complex, which helps stabilize the coenzyme and limits its rapid degradation.[24][26] Erythrocytes also contribute to vitamin B6 transport: PLP is taken up by red blood cells and binds to hemoglobin, which serves as an additional carrier to deliver the coenzyme to peripheral tissues.[27] At the level of target tissues, protein-bound PLP is again subject to dephosphorylation at or near the cellular surface, liberating PL, which can then enter the cell.[28] Inside the cell, PL is reconverted to PLP via the action of pyridoxal kinase, thereby regenerating the

metabolically active coenzyme form.[28] PLP is subsequently bound to a variety of intracellular proteins, including its cognate enzymes, which both positions it for catalysis and protects it from degradation by non-specific phosphatases.[28] This protein binding helps maintain intracellular PLP pools and ensures that the coenzyme is available where and when it is needed for enzymatic reactions. From a pharmacokinetic perspective, pyridoxine exhibits high oral bioavailability, reflecting its efficient gastrointestinal absorption and subsequent hepatic conversion to PLP. After ingestion, pyridoxine and related vitamers are taken up from the gut into the portal circulation and rapidly distributed. The liver is the primary storage site for vitamin B6, where substantial quantities of PLP and other forms are retained as part of normal metabolic homeostasis. Smaller but physiologically relevant amounts are also stored in the brain and skeletal muscles, where they serve ongoing roles in neurotransmitter synthesis and amino acid metabolism.[24]

Pyridoxine and its metabolites readily cross the placenta, indicating active or facilitated transfer from maternal to fetal circulation. Interestingly, fetal plasma concentrations of vitamin B6 and PLP can be several-fold higher—approximately five times—than maternal levels, highlighting the importance of this vitamin for fetal growth and neurodevelopment.[24] Vitamin B6 is also excreted into breast milk, thereby contributing to the nutritional requirements of the nursing infant. In the maternal circulation, a large proportion of vitamin B6, particularly PLP, is protein-bound, mainly to albumin, which contributes to its stability and regulates its free, bioactive fraction. Metabolically, pyridoxine and its related vitamers are ultimately inactivated primarily in the liver. PLP, after fulfilling its coenzymatic role, is dephosphorylated and oxidized to form 4-pyridoxic acid, the principal inactive catabolite of vitamin B6.[24] This metabolite does not possess coenzymatic function and represents the major end-product of pyridoxine metabolism. The inactivation and conversion to 4-pyridoxic acid thus constitute a key regulatory step in controlling overall vitamin B6 activity within the body. Excretion of vitamin B6 occurs mainly via the kidneys. The inactive 4-pyridoxic acid formed in the liver is eliminated in the urine, along with smaller quantities of other minor metabolites.[24] The elimination half-life of vitamin B6 in humans is relatively long—on the order of 15 to 20 days—reflecting its widespread tissue distribution, protein binding, and gradual metabolic turnover. This relatively prolonged half-life allows for some buffering against brief periods of reduced intake, although sustained deficiency states will eventually lead to depletion of tissue stores and clinical manifestations. In summary, the mechanism of action of vitamin B6 is centered on the biochemical versatility of PLP as an electron-withdrawing, Schiff base–forming coenzyme that accelerates a wide variety of amino acid transformations.[22] Its metabolic and pharmacokinetic profile is characterized by efficient intestinal absorption, hepatic conversion to PLP via pyridoxal kinase and PNP oxidase, transport in protein-bound form through plasma and erythrocytes, intracellular reconversion to the active coenzyme in target tissues, and eventual hepatic inactivation and renal excretion as 4-pyridoxic acid.[23][24][25][26][27][28] This integrated system ensures that PLP is available in sufficient quantities to support numerous critical reactions in intermediary metabolism, neurotransmitter synthesis, and energy production, while maintaining tight control over its distribution and turnover.

Administration

Vitamin B6 (pyridoxine) can be administered through multiple routes, with the choice of formulation and route tailored to the clinical context, patient status, and therapeutic objective. The oral route remains the most commonly employed modality, particularly in the prevention and treatment of mild deficiency states and for long-term supplementation. Parenteral routes—including intravenous (IV), intramuscular (IM), and, less frequently, subcutaneous administration—are reserved for specific indications, such as severe deficiency, malabsorption, acute neurologic presentations, or situations where oral intake is not feasible, such as in patients on total parenteral nutrition, those with anorexia, or individuals with significant gastrointestinal pathology. Oral pyridoxine is widely available in tablet form, most commonly as pyridoxine hydrochloride. Commercial formulations typically include strengths of 25 mg, 50 mg, 100 mg, and 500 mg per tablet, allowing flexible titration according to replacement, prophylactic, or high-dose therapeutic needs. These preparations are generally well absorbed from the gastrointestinal tract, making them suitable for routine supplementation and for many deficiency states in patients with intact absorption mechanisms. For hospitalized or critically ill patients, or in emergent toxicologic scenarios, parenteral formulations are preferred due to their rapid onset and reliable bioavailability. Injectable pyridoxine is commonly supplied in a concentration of 100 mg per mL, intended for administration either intravenously or intramuscularly, and can be used in acute care settings, particularly in seizure management related to pyridoxine-dependent syndromes or isoniazid toxicity. In adults, dosing strategy is guided by the underlying indication. For general dietary supplementation in individuals at risk but without overt deficiency, intake is best aligned with established Dietary Reference Intakes (DRIs), which consider age, sex, physiological status (e.g., pregnancy, lactation), and comorbid conditions. In

such cases, the total daily dose is typically achieved through a combination of dietary intake and low-dose oral supplements, often in multivitamin formulations that provide pyridoxine in the range of a few milligrams per day [27][28].

When nutritional inadequacy or overt deficiency is present, more structured replacement regimens are required. In such situations, pyridoxine hydrochloride may be administered via IM or IV injection, particularly at the start of therapy when rapid restoration of tissue stores is desired or oral intake is unreliable. A commonly recommended regimen for adults with nutritional vitamin B6 deficiency involves administering 10 to 20 mg of pyridoxine daily for approximately three weeks by parenteral route. This intensive repletion phase helps correct biochemical abnormalities and reverse clinical manifestations of deficiency, such as dermatitis, anemia, or neuropathy. Once metabolic status begins to normalize and oral intake is feasible, treatment is usually transitioned to an oral therapeutic multivitamin preparation containing 2 to 5 mg of pyridoxine daily for an additional period of several weeks. This consolidation phase supports stabilization of tissue levels and helps prevent relapse. Throughout this process, it is essential to concurrently address dietary quality by promoting a well-balanced, protein-adequate diet and correcting maladaptive eating patterns or contributory lifestyle behaviors, such as excessive alcohol use or restrictive intake. In vitamin B6–dependency syndromes, such as pyridoxine-dependent seizures, administration of pyridoxine assumes a pharmacologic rather than purely nutritional role. These conditions are characterized by inborn errors of metabolism in which enzyme function is markedly enhanced by supraphysiologic levels of PLP. In acute presentations associated with seizures, an initial IV dose of 100 mg pyridoxine is typically administered as a single bolus. If seizure activity persists or recurs, this dose may be repeated at intervals of 5 to 10 minutes, with careful monitoring of clinical response and cardiorespiratory status. The total cumulative dose in this acute setting should generally not exceed 500 mg to minimize the risk of adverse effects such as sensory neuropathy or hypotension. Following stabilization, maintenance regimens with lower oral doses are frequently instituted under specialist supervision to prevent recurrence [27][28].

Isoniazid (INH), a cornerstone agent in tuberculosis therapy, directly interferes with pyridoxine metabolism and PLP availability by forming hydrazones with pyridoxal phosphate. This interaction underlies both deficiency states and acute neurotoxicity associated with INH. In INH-induced vitamin B6 deficiency, standard practice is to administer a total daily dose of approximately 100 mg of pyridoxine for about three weeks, generally by oral or parenteral route depending on clinical status, followed by a maintenance dose of about 30 mg daily. This approach replenishes body stores and prevents progression of neurologic complications such as peripheral neuropathy. For prophylaxis of INH-induced neuropathy—especially in individuals at higher risk, such as those with diabetes, HIV, malnutrition, pregnancy, or alcoholism—lower daily doses are sufficient. Typical preventive dosing consists of 25 to 50 mg of pyridoxine orally once daily throughout the course of INH therapy. In patients who already exhibit signs of peripheral neuropathy, a higher maintenance dose of around 100 mg per day may be considered to provide more robust neuroprotection while INH treatment continues. In the context of acute INH poisoning, such as intentional or accidental ingestion of large quantities, pyridoxine is used as a specific antidote. When more than 10 g of isoniazid has been ingested, severe refractory seizures and metabolic acidosis can occur due to profound PLP depletion and inhibition of GABA synthesis. In such cases, the antidotal dosage of pyridoxine should ideally be equivalent on a gram-for-gram basis to the amount of INH ingested, where that information is available. When the exact dose of INH is unknown, a pragmatic regimen often adopted includes an initial administration of 4 g of pyridoxine intravenously, with additional doses of 1 g given intramuscularly at 30-minute intervals while closely monitoring neurologic and hemodynamic status. These high doses rapidly restore PLP-dependent GABA synthesis, helping to terminate seizures and stabilize the patient. Supportive care, including airway protection and management of acidosis, is provided concurrently [27][28].

Vitamin B6 has also been used off-label in the management of premenstrual syndrome (PMS), where it is thought to modulate neurotransmitter pathways involved in mood and somatic symptoms. Dosing regimens for this indication are highly variable in the literature and clinical practice. Reported daily doses range from as low as 40 mg up to 500 mg, administered orally, intravenously, or intramuscularly depending on clinical context and provider preference. While some studies report improvement in mood lability, irritability, and somatic discomfort with pyridoxine supplementation, others show inconsistent results. Given the potential for neuropathy with chronic high-dose use, treatment should be individualized, time-limited, and closely monitored, with doses kept as low as reasonably effective. Overall, the administration of vitamin B6 requires careful consideration of indication, route, and dose. For routine supplementation and mild deficiency, oral administration at physiologic or mildly supraphysiologic doses is generally sufficient and safe. For acute neurologic emergencies such as pyridoxine-dependent seizures or INH toxicity, high-dose parenteral administration is life-saving and must be delivered promptly according to established protocols. In all cases, therapy should be integrated into a broader clinical strategy that addresses

underlying causes, optimizes nutrition, and avoids prolonged unnecessary high-dose exposure that may predispose to toxicity, particularly sensory neuropathy [27][28].

Adverse Effects

Vitamin B6 (pyridoxine) is generally regarded as a safe and well-tolerated nutrient when consumed at physiologic or moderately supraphysiologic levels. However, as with many vitamins that serve as metabolic cofactors, excessive intake can result in toxicity, most notably involving the peripheral nervous system. The most widely recognized adverse effect associated with high-dose pyridoxine supplementation is sensory neuropathy, a predominantly axonal, length-dependent neuropathy that presents clinically with paresthesia, numbness, impaired proprioception, and gait disturbances. This adverse effect is strongly dose-dependent and occurs almost exclusively at supratherapeutic or toxic exposures. Toxicity has been documented primarily at daily intakes of 1 gram per day or more in adults, levels far exceeding those used in routine supplementation or clinical therapy. Current evidence indicates that neuropathy is exceedingly unlikely when pyridoxine is used at doses below 100 mg per day and for durations of less than 30 weeks in adults, highlighting a considerable margin of safety at commonly prescribed levels [19]. This safety margin is underscored by the fact that the average daily physiological requirement for vitamin B6 in adults is approximately 1.75 mg per day, an amount easily achieved through normal dietary intake [15]. Importantly, neither naturally occurring dietary levels nor standard supplemental doses of pyridoxine have been shown to cause toxicity. The body efficiently regulates and utilizes physiological quantities of vitamin B6, and adverse effects at these levels have not been observed. Nonetheless, intake of pyridoxine at higher but sub-toxic levels—although still significantly below those associated with neuropathy—may give rise to certain non-neurologic adverse effects. These reactions are typically mild, reversible, and dose-related. Reported symptoms include gastrointestinal discomfort such as indigestion or nausea, breast tenderness, increased photosensitivity, and dermatologic manifestations such as vesicular dermatoses. These side effects, while generally benign, can negatively impact adherence to supplementation if not anticipated and appropriately managed. The mechanisms underlying pyridoxine-induced neuropathy appear to relate to disruption of neuronal cell body function and interference with normal sensory nerve conduction, particularly within dorsal root ganglia. High circulating concentrations of pyridoxine are believed to competitively inhibit PLP-dependent enzymatic processes essential for neuronal maintenance. Fortunately, in the majority of reported cases, discontinuation of pyridoxine leads to gradual recovery of sensory function, although complete resolution may take months and, in severe cases, symptoms may persist [15].

Drug–Drug Interactions

Pyridoxine is involved in numerous metabolic pathways, and its pharmacologic use can influence the metabolism and therapeutic levels of several medications, creating clinically significant drug–drug interactions. One well-documented interaction occurs with certain anticonvulsant medications, particularly phenobarbital and phenytoin. Co-administration of pyridoxine with these antiepileptic agents can reduce plasma drug concentrations, likely through enhanced hepatic metabolism or altered coenzyme availability. This reduction in anticonvulsant levels may diminish seizure control and necessitate more frequent monitoring of serum drug concentrations or adjustments in dosing to maintain therapeutic efficacy. The clinical relevance of this interaction underscores the need for careful management of vitamin B6 supplementation in patients receiving long-term antiepileptic therapy. Another notable interaction occurs between pyridoxine and levodopa, a mainstay in the treatment of Parkinson disease. Pyridoxine enhances peripheral decarboxylation of levodopa, thereby reducing the amount of active drug reaching the central nervous system. This effect can attenuate the therapeutic benefit of levodopa, leading to worsened motor symptoms. However, the combination of levodopa with carbidopa—a peripheral dopa-decarboxylase inhibitor—effectively prevents this interaction. Carbidopa blocks the pyridoxine-dependent enzymatic conversion of levodopa in the periphery, allowing adequate delivery of levodopa to the brain. Thus, while pyridoxine can interfere with levodopa monotherapy, it has no significant impact on the commonly used levodopa–carbidopa combination. In summary, vitamin B6 is remarkably safe at nutritional and clinically appropriate supplemental doses, with toxicity occurring only at extreme intake levels. Awareness of its dose-dependent adverse effects and drug–drug interactions is essential for clinicians to optimize therapy, prevent complications, and ensure that patients receive the full therapeutic benefit of both pyridoxine and their concomitant medications [18].

Contraindications

Vitamin B6 (pyridoxine) is considered safe when used within recommended dietary and therapeutic ranges; however, certain clinical situations necessitate caution or complete avoidance. The primary contraindication is the presence of hypervitaminosis B6, a condition characterized by excessive accumulation of pyridoxine that may lead to progressive sensory neuropathy. At toxic concentrations, vitamin B6 can disrupt neuronal function, producing paresthesia, impaired proprioception, and gait disturbances. Therefore,

patients exhibiting signs or laboratory evidence of pyridoxine toxicity should not receive additional supplementation until serum levels normalize and symptoms resolve. Another important contraindication is hypersensitivity to pyridoxine or any component of the formulation. Although rare, allergic reactions may manifest as dermatologic eruptions, pruritus, or systemic hypersensitivity responses; in such cases, further administration should be avoided. Special considerations also apply to pregnant and breastfeeding individuals. While vitamin B6 is widely used during pregnancy—for example, in combination with doxylamine for the management of nausea and vomiting—patients are advised not to exceed recommended doses without medical supervision. Excessive intake during pregnancy or lactation may pose theoretical risks, and individualized clinical guidance is essential to ensure both maternal and fetal safety [18].

Precautions

Clinicians should recognize that vitamin B6 deficiency rarely occurs in isolation, as it is commonly associated with broader nutritional inadequacies. Patients with poor dietary intake often exhibit multiple micronutrient deficiencies, and supplementation should be approached comprehensively rather than targeting pyridoxine alone. A significant precaution involves individuals receiving levodopa for Parkinson disease. Pyridoxine enhances peripheral conversion of levodopa to dopamine, thereby reducing the amount of active drug that reaches the central nervous system. For this reason, patients on levodopa monotherapy should avoid pyridoxine doses exceeding 5 mg per day. Although the levodopa–carbidopa combination largely eliminates this interaction, caution remains advisable. In women using oral contraceptives, an increased metabolic demand for pyridoxine has been observed. These patients may require additional dietary intake or supplementation to maintain adequate vitamin B6 status, although supplementation should still be guided by clinical assessment to avoid excessive dosing. Overall, awareness of these contraindications and precautions is essential for safe prescribing practices and for preventing adverse outcomes associated with improper vitamin B6 administration [19][20][21].

Monitoring

Monitoring vitamin B6 (pyridoxine) status is an important aspect of safe and effective clinical use, particularly because its therapeutic index varies considerably among individuals. Susceptibility to toxic adverse effects such as sensory neuropathy is not uniform, and interindividual variability has been clearly documented. Some studies suggest that a cumulative exposure threshold of approximately 100 grams over a period of 20 months represents a practical cutoff below which neuropathy related to pyridoxine toxicity is unlikely to occur, although this should not be interpreted as an absolute guarantee of safety in all patients.[29][19] This variability underscores the need for thoughtful clinical monitoring when high-dose or prolonged supplementation is used. Vitamin B6 is highly bioavailable from both dietary sources and pharmacologic preparations. It is efficiently absorbed in the small intestine, and high plasma concentrations can be reached relatively quickly, particularly when large supplemental doses are administered.[30] Under normal physiologic conditions, excess pyridoxine is metabolized in the liver to 4-pyridoxic acid and excreted in the urine. At very high doses, a proportion may also be eliminated unchanged. This efficient renal clearance provides some protection against accumulation, but it does not fully prevent toxicity when intake far exceeds metabolic needs for extended periods, especially in susceptible individuals or in those with impaired renal function. Monitoring of vitamin B6 status is undertaken for three principal reasons: to confirm deficiency in symptomatic or at-risk patients, to detect toxicity in those receiving high-dose therapy, and to support research exploring the relationships between B6 status and disease processes.[30] Assessment strategies are broadly divided into direct and functional methods, each providing complementary information about body stores and metabolic sufficiency.

Direct monitoring methods quantify vitamin B6 or its metabolites in biological fluids or cells. These include measurement of pyridoxal 5-phosphate (PLP), pyridoxal (PL), and other vitamers in plasma, whole blood, erythrocytes, or urine. Among these, plasma PLP concentration is considered the most informative and widely accepted index of vitamin B6 status, as it correlates well with total body B6 stores and reflects both recent intake and tissue sufficiency.[31] Low plasma PLP values are typically indicative of deficiency, whereas markedly elevated levels may raise concern for excessive intake or altered metabolism. Urinary excretion of 4-pyridoxic acid can also provide insight into recent intake and saturation of metabolic pathways but is more often used in research than routine clinical practice. Functional assessment methods evaluate the metabolic consequences of inadequate PLP availability rather than the absolute concentration of the vitamin. These tests are particularly useful when direct measurements are equivocal or when clinicians seek evidence of impaired coenzyme function. Classical functional tests include the tryptophan load test, plasma homocysteine levels, and assays of PLP-dependent enzyme activities. The tryptophan load test relies on the fact that several enzymes in the kynurenine pathway require PLP; in vitamin B6 deficiency, abnormal metabolites such as xanthurenic acid accumulate following a tryptophan challenge. Similarly, elevated plasma homocysteine levels may reflect impaired PLP-dependent transsulfuration

pathways, especially when folate and vitamin B12 deficiencies have been excluded.[31]

Another key group of functional indicators involves PLP-dependent transaminases, especially erythrocyte aspartate aminotransferase (AST) and alanine aminotransferase (ALT). In vitro stimulation or activation tests measure the increase in transaminase activity after adding exogenous PLP to the assay. A significant rise in activity suggests that enzyme function was limited by insufficient endogenous PLP, thereby indicating tissue-level vitamin B6 depletion. These erythrocyte AST and ALT stimulation tests are valuable in assessing long-term B6 status, as they integrate information over time rather than reflecting only short-term intake.[31] In clinical settings where parenteral vitamin B6 is administered, additional monitoring considerations arise due to excipients in the formulation. Many parenteral nutrition solutions and injectable vitamin preparations may contain aluminum as a contaminant, which can accumulate in the body over time. Aluminum is renally excreted and can be toxic, particularly to the central nervous system and skeletal system. Prolonged exposure through parenteral routes is of special concern in patients with reduced kidney function who cannot adequately eliminate the metal. Premature neonates are especially vulnerable, as their renal function is immature and unable to manage sustained aluminum loads effectively. Studies indicate that individuals with impaired renal function, including preterm infants, who receive parenteral aluminum at doses exceeding 4 to 5 mcg/kg/day can accumulate levels associated with neurotoxicity and bone disease.[30] Notably, even administration below these thresholds over long periods may result in gradual tissue accumulation.

Therefore, when vitamin B6 is delivered as part of parenteral nutrition or other intravenous formulations, careful attention must be given to total aluminum exposure from all parenteral sources. Monitoring in these patients includes regular assessment of renal function, surveillance for neurologic changes, and consideration of bone health, particularly in long-term recipients. Whenever possible, formulations with minimized aluminum content should be selected, especially for neonates, infants, and patients with chronic kidney disease. From a clinical standpoint, monitoring patients receiving high-dose pyridoxine or long-term supplementation should extend beyond laboratory testing alone. Regular neurologic examinations are essential, with particular attention to new-onset paresthesia, numbness, loss of vibration sense, impaired balance, or gait disturbances suggestive of developing sensory neuropathy. Early recognition of these symptoms should prompt reevaluation of dosing and consideration of gradual reduction or discontinuation of vitamin B6 supplementation. In patients treated for conditions such as vitamin B6–dependent seizures, where high doses are necessary, close neurologic follow-up is critical to balancing therapeutic benefit with the risk of toxicity. In populations at risk of deficiency—such as individuals with malabsorption, chronic alcohol use, certain autoimmune diseases, or long-term therapy with drugs that interfere with B6 metabolism—periodic assessment of B6 status may be warranted. In these groups, monitoring may focus on clinical features of deficiency (e.g., glossitis, seborrheic dermatitis, microcytic anemia, neuropathy, mood changes) complemented by selected laboratory tests such as plasma PLP or functional assays when available. Overall, monitoring vitamin B6 is a multifaceted process that integrates biochemical, functional, and clinical data. Direct measurements, especially plasma PLP, provide a reliable estimation of body stores, while functional tests elucidate the metabolic impact of deficiency or inadequate coenzyme availability. In special populations, such as premature neonates or patients on parenteral nutrition, monitoring must also account for excipient-related risks such as aluminum toxicity. Through vigilant, individualized monitoring, clinicians can optimize the therapeutic use of pyridoxine, prevent both deficiency and toxicity, and ensure safe long-term management in patients who depend on vitamin B6–containing therapies.[29][19][30][31]

Toxicity

Vitamin B6 toxicity, though uncommon at standard dietary or supplemental doses, becomes clinically significant when excessive amounts accumulate in the body over time. The hallmark manifestation of pyridoxine toxicity is sensory neuropathy, a condition characterized by dysfunction of peripheral sensory nerves. Although the precise pathophysiological mechanism remains incompletely understood, research suggests that excessively high concentrations of pyridoxine may induce degeneration of sensory nerve fibers, disrupt myelin integrity, and impair the dorsal columns of the spinal cord.[16] This pattern of neurotoxicity manifests clinically as bilateral loss of peripheral sensation, hyperesthesia, painful dysesthesias of the limbs, gait ataxia, and impaired balance. Patients may report numbness, tingling, burning sensations, or difficulty with coordinated movements. Importantly, these symptoms typically develop insidiously and progress gradually with continued exposure to high-dose vitamin B6. The severity of neuropathy correlates with both the cumulative dose and the duration of supplementation, indicating a clear dose-response relationship. Studies demonstrate that prolonged intake of large doses is a key determinant of clinically apparent toxicity, with the total cumulative amount being more predictive of symptoms than short-term intake fluctuations.[19] Once pyridoxine supplementation is discontinued, sensory symptoms often improve; however, recovery can be slow,

requiring several months before normal neurologic function is reestablished. In some cases, residual deficits may persist if toxicity has been severe or prolonged.

In addition to neurologic effects, higher doses of vitamin B6 have been associated with other adverse outcomes, including testicular atrophy and impaired sperm motility in males.[32] These findings, though less common, underscore the systemic consequences of excessive pyridoxine exposure. As vitamin B6 is widely available over the counter and frequently perceived as benign, unregulated long-term high-dose use poses a risk, particularly among individuals self-treating nonspecific symptoms or using megavitamin regimens. Given the potential for harm, clinicians should remain aware of toxicity risks when prescribing or monitoring pyridoxine therapy, especially in patients receiving doses far exceeding physiological requirements. Careful attention to dose, duration, and early neurologic symptoms is essential to prevent irreversible complications and ensure safe, evidence-based use of vitamin B6.

Enhancing Healthcare Team Outcomes

Optimizing outcomes in the prevention, diagnosis, and management of vitamin B6–related disorders depends heavily on an integrated, well-coordinated interprofessional approach. Although frank vitamin B6 deficiency from dietary inadequacy is relatively uncommon in the general population, it remains clinically relevant in specific at-risk groups, and excessive or inappropriate supplementation can also lead to toxicity. Accordingly, clinicians, nurses, pharmacists, and dietitians must collaborate closely, sharing information and aligning strategies to ensure safe and effective use of pyridoxine across diverse clinical settings. A foundational element in improving outcomes is the promotion of adequate nutrition. Because vitamin B6 is widely available in common foods—such as chickpeas, poultry, fish, liver, potatoes, bananas, and fortified cereals—most individuals can meet their daily requirements through a balanced diet. Primary care clinicians and dietitians play a key role in counseling patients on food-based sources of vitamin B6, particularly those with limited dietary diversity, low socioeconomic resources, restrictive diets, or chronic illnesses that predispose them to micronutrient deficiencies. Nurses reinforce this education during inpatient care and follow-up visits, translating dietary recommendations into practical advice that fits patients' cultural preferences and daily routines [30].

Specialist physicians—such as gynecologists, obstetricians, neurologists, hematologists, psychiatrists, and dermatologists—are frequently involved in cases where vitamin B6 deficiency or excess presents with complex or nonspecific clinical features. For example, neurologists may see patients with peripheral neuropathy or seizures; hematologists may evaluate unexplained microcytic or sideroblastic anemia; dermatologists may encounter seborrheic-like dermatoses; and gynecologists or obstetricians may consider pyridoxine for nausea of pregnancy or premenstrual symptoms. Because these manifestations are not unique to vitamin B6 deficiency, careful differential diagnosis is required. Collaborative case discussions, shared electronic health records, and interdisciplinary case conferences can help clinicians integrate neurologic, hematologic, dermatologic, nutritional, and psychosocial data to arrive at an accurate diagnosis. Identifying high-risk populations is another crucial responsibility of the interprofessional team. Patients with chronic illnesses such as renal failure, malabsorption syndromes, autoimmune disease, chronic alcoholism, or long-term therapy with medications that interfere with B6 metabolism (e.g., isoniazid, certain antiepileptics, hydralazine) are particularly vulnerable to deficiency. Similarly, patients engaging in unsupervised high-dose supplementation or megavitamin regimens may be at risk for toxicity. Nurses and pharmacists are often the first to recognize patterns of polypharmacy, over-the-counter supplement use, and adherence issues that may not emerge during brief physician encounters. When these concerns are communicated effectively to the prescribing clinician and dietitian, timely adjustments in therapy and targeted education can prevent complications [30].

Although clinical use of high-dose vitamin B6 in certain conditions—such as premenstrual syndrome, gestational diabetes, carpal tunnel syndrome, mood disorders, and various neurologic or metabolic syndromes—remains controversial, pyridoxine is frequently prescribed because it is water-soluble and generally perceived as safe. This perception, however, should not eliminate the need for thoughtful oversight. In recognized vitamin B6–dependency syndromes or inborn errors of metabolism, doses far exceeding normal dietary requirements are necessary to restore enzyme activity and prevent severe neurologic or metabolic decompensation. In such cases, neurologists and metabolic specialists must work closely with pharmacists, nurses, and primary care providers to monitor for early signs of sensory neuropathy or other adverse effects while preserving the therapeutic benefit. Pharmacists play a central role in evaluating total pyridoxine exposure from prescribed medications, compounded formulations, and over-the-counter supplements. They can identify potential drug–nutrient interactions, such as the antagonism of levodopa by high-dose pyridoxine in patients not receiving carbidopa, or the impact of pyridoxine on certain antiepileptic drug levels. Pharmacists are also strategically positioned to counsel patients about appropriate dosing, duration of therapy, and the risks of self-escalation of dose. Their input is vital in establishing institutional policies for standardized dosing in high-risk situations, such as prophylaxis of

isoniazid-induced neuropathy, treatment of isoniazid overdose, or parenteral nutrition protocols. Nurses serve as the frontline observers of clinical response and potential toxicity. Through repeated patient interactions, they are uniquely able to detect subtle changes, such as new-onset paresthesia, gait instability, mood disturbances, skin changes, or poor adherence to dietary recommendations. Bedside nurses in hospitals and community nurses in home-care settings can provide ongoing reinforcement of education, ensure correct administration of prescribed doses, and promptly escalate concerns about possible adverse effects or insufficient response. Their documentation of symptoms and patient-reported outcomes feeds back into the decision-making process of the entire team [30].

Dietitians and nutritionists extend this monitoring to the realm of overall dietary patterns, micronutrient balance, and comorbid nutritional deficiencies. They are integral to creating individualized nutrition care plans that incorporate adequate vitamin B6 intake without unnecessary reliance on high-dose supplementation. In patients with complex nutritional needs—such as those on enteral or parenteral nutrition—dietitians collaborate with pharmacists and physicians to design regimens that provide appropriate amounts of pyridoxine while minimizing risks associated with contaminants or excessive dosing. Communication and shared decision-making are at the heart of improving healthcare team outcomes. All interprofessional team members must have access to the same up-to-date clinical information, including laboratory results, medication lists, supplement use, nutritional assessments, and documented symptoms. Integrated electronic health records and clearly defined care pathways facilitate this process. Regular interprofessional meetings, case reviews, and feedback loops enable continuous refinement of protocols for vitamin B6 use, especially in vulnerable populations such as pregnant women, the elderly, patients with renal impairment, and those with neurologic or metabolic disorders. Patient education and engagement further enhance outcomes. When vitamin B6 is prescribed for therapeutic purposes or used as a supplement, patients should receive consistent, clear messaging from all members of the team about why it is being used, how long it should be taken, and what signs of deficiency or toxicity to watch for. Encouraging patients to disclose all supplements, herbal preparations, and dietary practices is essential for accurate assessment. Empowering them with knowledge about food sources, realistic expectations of benefit, and the dangers of exceeding recommended doses promotes safer use and better adherence. Ultimately, whether vitamin B6 is used as part of nutritional support, in specific dependency syndromes, or as an adjunctive therapy in controversial indications, optimal outcomes depend on coordinated interprofessional care. Prescribing clinicians, nurses, pharmacists, and dietitians must work as a cohesive unit, sharing responsibility for monitoring efficacy and safety, reinforcing evidence-based guidance, and maintaining vigilance for potential adverse effects. Through this collaborative framework, the healthcare team can maximize the benefits of vitamin B6, minimize harm, and deliver patient-centered care that aligns with best practices in nutrition, pharmacology, and clinical medicine [30].

Conclusion:

In conclusion, vitamin B6 is a micronutrient of profound metabolic importance, with its active coenzyme PLP integral to a vast array of biochemical processes. Its clinical utility is firmly established in the correction of nutritional and drug-induced deficiencies, the management of inborn errors of metabolism (B6-dependency syndromes), and as a specific antidote in acute isoniazid poisoning. The FDA-approved combination with doxylamine for pregnancy-related nausea further underscores its therapeutic value. However, the evidence supporting its use in many other conditions, such as premenstrual syndrome, carpal tunnel syndrome, or mood disorders, remains limited and inconclusive, positioning it as an adjunct rather than a primary therapy in these contexts. A critical consideration in clinical practice is its safety profile. While generally well-tolerated, vitamin B6 exhibits a clear dose-dependent toxicity, with chronic high-dose intake leading to a predominantly sensory neuropathy that may be irreversible. This underscores the necessity for judicious prescribing, patient education against unmonitored high-dose supplementation, and vigilant monitoring for neurological symptoms. Ultimately, optimizing patient outcomes requires an interprofessional approach where clinicians, pharmacists, dietitians, and nurses collaborate to ensure appropriate use, differentiate between established and unproven indications, and balance efficacy with the prevention of adverse effects.

References:

1. SNELL EE. Chemical structure in relation to biological activities of vitamin B6. Vitamins and hormones. 1958:16():77-125
2. RABINOWITZ JC, SNELL EE. The vitamin B6 group; microbiological and natural occurrence of pyridoxamine phosphate. The Journal of biological chemistry. 1947 Aug:169(3):643-50
3. SNELL EE. Summary of known metabolic functions of nicotinic acid, riboflavin and vitamin B6. Physiological reviews. 1953 Oct:33(4):509-24
4. Ebadi M. Regulation and function of pyridoxal phosphate in CNS. Neurochemistry international. 1981:3(3-4):181-205
5. Wibowo N, Purwosunu Y, Sekizawa A, Farina A, Tambunan V, Bardosono S. Vitamin B_6 supplementation in pregnant women with nausea and vomiting. International journal of gynaecology and obstetrics: the official organ of the International

Federation of Gynaecology and Obstetrics. 2012 Mar:116(3):206-10. doi: 10.1016/j.ijgo.2011.09.030.
6. Matthews A, Haas DM, O'Mathúna DP, Dowswell T, Doyle M. Interventions for nausea and vomiting in early pregnancy. The Cochrane database of systematic reviews. 2014 Mar 21:(3):CD007575. doi: 10.1002/14651858.CD007575.pub3.
7. Snider DE Jr. Pyridoxine supplementation during isoniazid therapy. Tubercle. 1980 Dec:61(4):191-6
8. Raskin NH, Fishman RA. Pyridoxine-deficiency neuropathy due to hydralazine. The New England journal of medicine. 1965 Nov 25:273(22):1182-5
9. Nair S, Maguire W, Baron H, Imbruce R. The effect of cycloserine on pyridoxine-dependent metabolism in tuberculosis. Journal of clinical pharmacology. 1976 Aug-Sep:16(8-9):439-43
10. Clayton PT. B6-responsive disorders: a model of vitamin dependency. Journal of inherited metabolic disease. 2006 Apr-Jun:29(2-3):317-26
11. Apeland T, Frøyland ES, Kristensen O, Strandjord RE, Mansoor MA. Drug-induced pertubation of the aminothiol redox-status in patients with epilepsy: improvement by B-vitamins. Epilepsy research. 2008 Nov:82(1):1-6. doi: 10.1016/j.eplepsyres.2008.06.003.
12. MUELLER JF, VILTER RW. Pyridoxine deficiency in human beings induced with desoxypyridoxine. The Journal of clinical investigation. 1950 Feb:29(2):193-201
13. Hawkins WW, Barsky J. An Experiment on Human Vitamin B6 Deprivation. Science (New York, N.Y.). 1948 Sep 10:108(2802):284-6
14. Riikonen R, Mankinen K, Gaily E. Long-term outcome in pyridoxine-responsive infantile epilepsy. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. 2015 Nov:19(6):647-51. doi: 10.1016/j.ejpn.2015.08.001.
15. Frimpter GW, Andelman RJ, George WF. Vitamin B6-dependency syndromes. New horizons in nutrition. The American journal of clinical nutrition. 1969 Jun:22(6):794-805
16. Lheureux P, Penaloza A, Gris M. Pyridoxine in clinical toxicology: a review. European journal of emergency medicine : official journal of the European Society for Emergency Medicine. 2005 Apr:12(2):78-85
17. Bender DA. Non-nutritional uses of vitamin B6. The British journal of nutrition. 1999 Jan:81(1):7-20
18. Salam RA, Zuberi NF, Bhutta ZA. Pyridoxine (vitamin B6) supplementation during pregnancy or labour for maternal and neonatal outcomes. The Cochrane database of systematic reviews. 2015 Jun 3:2015(6):CD000179. doi: 10.1002/14651858.CD000179.pub3.
19. Bendich A, Cohen M. Vitamin B6 safety issues. Annals of the New York Academy of Sciences. 1990:585():321-30
20. Larsson SC, Orsini N, Wolk A. Vitamin B6 and risk of colorectal cancer: a meta-analysis of prospective studies. JAMA. 2010 Mar 17:303(11):1077-83. doi: 10.1001/jama.2010.263.
21. Tryfiates GP. Effects of pyridoxine on serum protein expression in hepatoma-bearing rats. Journal of the National Cancer Institute. 1981 Feb:66(2):339-44
22. Hayashi H, Wada H, Yoshimura T, Esaki N, Soda K. Recent topics in pyridoxal 5'-phosphate enzyme studies. Annual review of biochemistry. 1990:59():87-110
23. Hamm MW, Mehansho H, Henderson LM. Transport and metabolism of pyridoxamine and pyridoxamine phosphate in the small intestine of the rat. The Journal of nutrition. 1979 Sep:109(9):1552-9
24. Buss DD, Hamm MW, Mehansho H, Henderson LM. Transport and metabolism of pyridoxine in the perfused small intestine and the hind limb of the rat. The Journal of nutrition. 1980 Aug:110(8):1655-63
25. Tsuji T, Yamada R, Nose Y. Intestinal absorption of vitamin B6. I. Pyridoxol uptake by rat intestinal tissue. Journal of nutritional science and vitaminology. 1973 Oct:19(5):401-17
26. Mehansho H, Buss DD, Hamm MW, Henderson LM. Transport and metabolism of pyridoxine in rat liver. Biochimica et biophysica acta. 1980 Aug 1:631(1):112-23
27. Mehansho H, Henderson LM. Transport and accumulation of pyridoxine and pyridoxal by erythrocytes. The Journal of biological chemistry. 1980 Dec 25:255(24):11901-7
28. Li TK, Lumeng L, Veitch RL. Regulation of pyridoxal 5'-phosphate metabolism in liver. Biochemical and biophysical research communications. 1974 Nov 27:61(2):677-84
29. . Sensory neuropathy from pyridoxine abuse. The New England journal of medicine. 1984 Jan 19:310(3):197-8
30. Ink SL, Henderson LM. Vitamin B6 metabolism. Annual review of nutrition. 1984:4():455-70
31. Ueland PM, Ulvik A, Rios-Avila L, Midttun Ø, Gregory JF. Direct and Functional Biomarkers of Vitamin B6 Status. Annual review of nutrition. 2015:35():33-70. doi: 10.1146/annurev-nutr-071714-034330.
32. Tsutsumi S, Tanaka T, Gotoh K, Akaike M. Effects of pyridoxine on male fertility. The Journal of toxicological sciences. 1995 Aug:20(3):351-65.